Cervical cancer is among the most preventable cancers in existence. The human papillomavirus (HPV) vaccine, first approved in 2006, prevents infection with the viral strains responsible for approximately 90% of cervical cancers. Regular Pap smears and HPV co-testing can identify precancerous changes before they progress. The tools to eliminate most cervical cancer deaths exist and are not new.
Yet approximately 4,000 American women die of cervical cancer every year. The deaths are not random. They are concentrated in Black women, Hispanic women, women in rural areas, women without insurance, and women in low-income communities — populations with unequal access to vaccination and screening.
Vaccination: A Prevention Story Interrupted by Access
HPV vaccination rates in the United States remain below targets, and uptake is unequal in ways that closely track cervical cancer mortality. Rural adolescents are less likely to be vaccinated than urban peers. Uninsured children receive vaccines at lower rates. Provider recommendation — the single most important predictor of HPV vaccine uptake — is inconsistent, particularly in primary care settings serving underserved populations.
The expansion of HPV vaccination to adults through age 45 has created new prevention opportunities that are not being fully realized. Women in their 30s and 40s who missed vaccination in adolescence may benefit from catch-up vaccination — but many are unaware of their eligibility, and clinician counseling on adult HPV vaccination remains inconsistent.
Cervical Cancer and the Racial Mortality Gap
Black women are diagnosed with cervical cancer at higher rates than white women and die from it at significantly higher rates. The disparity is not primarily biological. It reflects lower rates of screening, later-stage diagnosis, differential access to treatment, and a health system in which the populations with the highest disease burden receive the least prevention infrastructure.
Rural women across racial groups face a compounding access crisis: fewer OB-GYN providers, longer travel distances to screening facilities, and lower insurance rates. The closures of rural hospitals and rural health clinics in recent years have further eroded the screening infrastructure on which cervical cancer prevention depends.
Prevention Infrastructure Is Health Infrastructure
Eliminating cervical cancer deaths is achievable. Australia has demonstrated that a sustained, equity-focused national vaccination and screening program can drive cervical cancer toward elimination. The United States has the vaccine and the screening technology. What it lacks is the policy commitment to make prevention equally accessible to every woman, regardless of income, geography, or insurance status.
Cervical cancer deaths in 2024 are not a medical failure. They are a policy choice.
